Many authors subsequently focused their efforts on this topic, and all of these studies may be grouped based on the four main features addressed72: identification of CTX in patients previously treated with oncologic therapies; serial evaluations for the prospective early recognition of myocardial damage; prediction of late CTX development; and planning of cardioprotection strategies.
The first group of studies demonstrated that 2D STE was more sensitive than LVEF reduction for the early recognition of asymptomatic left ventricle systolic dysfunction caused by chemotherapy in children and adults. 2D STE detected subclinical systolic myocardial abnormalities in children with acute lymphoblastic leukaemia and adult patients with breast cancer when no significant alterations were detected in conventional echocardiographic parameters.74–76
Although few data on evaluations of cardioprotection using 2D STE are available, Negishi et al.82 recently demonstrated that LVEF and GLS improved in patients receiving anthracycline, trastuzumab or both after approximately 1 year of beta-blocker treatment. These results suggest a protective role of this therapy in these patients, but the results should be evaluated in larger populations.
There is only limited experience with the use of rotational and torsional indices in this setting. Mornos et al.83 tried to combine GLS and left ventricle twisting to obtain a new index to evaluate cardiac function before and after 6, 12, 24 and 52 weeks of anthracycline treatment, and they identified an early deterioration of GLS multiplied by left ventricle twisting as the best predictor of later CTX. 3D STE enables the derivation of an index of left ventricle global performance that incorporates left ventricle 3D strain, dyssynchrony and torsion for the sensitive detection of altered left ventricle mechanics in childhood cancer survivors,84 although rotational indexes are currently used only for research, and further studies are needed to establish their role in the detection of CTR-CD.
In conclusion, the use the same vendor's machine and software version is presently recommended to compare individual patients with cancer when using 2D STE for the serial evaluation of systolic function.85
3D echocardiography is more accurate than the 2D modality for left ventricle volume and ejection fraction measurements, and it exhibits a precision that is comparable to CMR (Fig. 5).86 Advantages include better accuracy in LVEF measurements below the lower normal limits, superior reproducibility and lower temporal variability. The improved accuracy of 3D over 2D echocardiography for the detection of LVEF less than 50% was observed in survivors of childhood cancer.87 The preeminence of 3D echocardiography may be explained by the fact that it is less affected by acquisition differences from one scan to the next. Moreover, the use of an automated or semiautomated method for the identification of the left ventricle endocardium, compared with the manual tracing of endocardial contour that is required by the 2D method, provides a more accurate estimation of left ventricle volumes.88,89 Notably, 3D echocardiography is the technique of choice for the monitoring of the cardiac effects of chemotherapy. Serial 3D echocardiographic calculations of LVEF should be encouraged for the monitoring of cardiac toxicity where available,2 although it is important to realise that this technology needs high-quality images and training and expertise of operators for clinical application in the oncological setting. These concerns limit the widespread application of 3D echocardiography in the oncological setting.
Other imaging modalities, such as radionuclide angiography (MUGA), were referred to as the ‘gold standard’ to evaluate left ventricle systolic function in patients undergoing chemotherapy for many years.90 Serial imaging using MUGA effectively monitors anthracyclines-related damage because of its high accuracy and reproducibility of LVEF measurements. The main disadvantage of MUGA is radiation exposure, which reduces its use given the increasing availability of other imaging techniques. MUGA also does not provide comprehensive information on right ventricle function, left and right atrial size, and the presence or absence of valvular or pericardial disease. Therefore, it is frequently used as an adjunct and complementary technique to echocardiography.
CMR is currently considered the reference standard in assessing left ventricle and right ventricle volumes and function, and it was recently used more extensively to detect the acute and chronic complications of cardiotoxic chemotherapeutic agents.91 CMR is superior to echocardiography for its wide field of view, flexible scanning planes, and lack of ionising radiation.92 Contrast-enhanced CMR offers a unique capability to assess myocardial tissue characteristics because it possesses an excellent ability to outline myocardial oedema, hyperaemia, iron and necrosis/fibrosis, although this method has several limitations, such as low availability and a higher operational cost, compared with echocardiography. Issues with claustrophobia and hazards associated with ferromagnetic devices in some patients with cancer (e.g. breast tissue expanders used for breast reconstruction after mastectomy) must be considered.
The use of different imaging techniques, such as echocardiography, MUGA and CMR, to evaluate left ventricle volumes and LVEF values in the same patient is not suggested because of the significant difference in results across the techniques. Therefore, the choice of a single tool for the serial monitoring of LVEF during chemotherapy is preferred. Much evidence suggests that CMR should be considered in situations in which the discontinuation of chemotherapeutic regimens secondary to CTX is entertained or when the estimation of the LVEF is controversial or unreliable because of the low quality of echocardiographic images.2,93
International scientific societies finally began to state positions on the issue of echocardiographic monitoring during the course of chemotherapy in response to the growing evidence that the evaluation of the LVEF alone is no longer sufficient to identify chemotherapy-related early myocardial damage.
The two largest scientific societies of echocardiography, the ASE and EACVI, worked together to produce a shared document for the first time and stated positions on the role of various echocardiographic indices in this setting.2
Echocardiography was identified as the method of choice to evaluate patients before, during and after cancer therapy, and ejection fraction remained the first and irreplaceable technique. Ejection fraction should be performed using the best available method in the echocardiography laboratory (ideally 3D) in combination with the calculation of the wall motion score index.
LVEF failed to predict the development of CTR-CD. Therefore, a deeper echocardiographic investigation was strongly suggested, when available, to integrate the standard examination with data from different imaging techniques, such as TDI and STE.
The use of diastolic indices was not useful for the early detection of CTX because of their inability to predict subsequent heart failure.
Many studies during chemotherapy demonstrated reductions in all three myocardial layers, but neither radial nor circumferential strains were predictive of subsequent dysfunction. Therefore, the joint ASE/EACVI consensus suggests only the use of GLS by STE for a sensitive diagnosis of CTR-CD, and the same vendor-specific ultrasound machine should be used for serial examinations.
Patients who must undergo chemotherapy should first be evaluated by echocardiography and should be followed during and after the treatment with serial echocardiograms performed with a timing decided according to single patient's clinical conditions.
The first examination should be as complete as possible and must include the study of the: systolic function, by LVEF and GLS, diastolic function, heart valves, pericardium and right chambers.
Later checks ought to have to be guided by the results of the baseline examination. In each case, the assessment of systolic function and the pericardium must always be included. 3D echocardiography should be preferred when available for the calculation of volumes and ejection fraction. Is preferable that serial examinations are carried out always with the same echocardiographic system. The evidence of CTR-CD should be discussed with oncologist to decide whether the discontinuation of therapy is needed.
The issue of the diagnosis of CTR-CD is absolutely topical. Recent evidence of the importance of early diagnosis and strict follow-up in these patients have produced in an increasing effort to define a protocol to provide cardiologists and oncologists a prompt diagnosis and better patient management, including eventual cardioprotection therapy.94,95 Echocardiography plays a first-line role in cases with such a pressing indication.
There are no conflicts of interest.
1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol
2. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr
3. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr
4. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation
5. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol
6. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr
7. Di Lisi D, Bonura F, Macaione F, et al. Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the tissue Doppler. Minerva Cardioangiol
8. Di Lisi D, Leggio G, Vitale G, et al. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction. J Cardiovasc Med (Hagerstown)
9. Di Lisi D, Bonura F, Macaione F, et al. Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs
10. Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol
11. Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol
12. Lipshultz SE, Sanders SP, Goorin AM, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics
13. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol
14. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf
15. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev
16. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: Nsabp b-31. J Clin Oncol
17. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol
18. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol
19. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer
20. Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol
21. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer
22. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol
23. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol
24. Ishii M, Tsutsumi T, Himeno W, et al. Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol
25. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart
26. Rohde LE, Baldi A, Weber C, et al. Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction: diagnosis of adriamycin cardiotoxicity. Int J Cardiovasc Imaging
27. Nagy AC, Cserep Z, Tolnay E, et al. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res
28. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol
29. Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr
30. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med
31. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multimodality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging
32. Tomlinson D, Mermel LA, Ethier MC, et al. Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review. Clin Infect Dis
33. Safdar A. Principles and practice of cancer infectious diseases current clinical oncology
. Humana Press; 2011. pp. 219–232.
34. Edoute Y, Haim N, Rinkevich D, et al. Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med
35. Biller J, Challa VR, Toole JF, et al. Nonbacterial thrombotic endocarditis. A neurologic perspective of clinicopathologic correlations of 99 patients. Arch Neurol
36. Reagan TJ, Okazaki H. The thrombotic syndrome associated with carcinoma. A clinical and neuropathologic study. Arch Neurol
37. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore)
38. el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and Treatment. Oncologist
39. Aleman BMP, Van den Belt-Dusebout AW, Klokman WJ, et al. L.ong-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol
40. Cella L, Oh JH, Deasy JO, et al. Predicting radiation-induced valvular heart damage. Acta Oncol
41. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol
42. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA
43. Tamura A, Takahara Y, Mogi K, Katsumata M. Radiation-induced valvular disease is the logical consequence of irradiation. General Thoracic and Cardiovascular Surgery
44. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol
45. Malanca M, Cimadevilla C, Brochet E, et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr
46. Forman M, Virmani R, Robertson R, Stone W. Mitral annular calcification in chronic renal failure. Chest
47. Fulkerson P, Beaver B, Auseon J, Graber H. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med
48. Tanindi A, Demirci U, Tacoy G, et al. Assessment of right ventricular functions during cancer chemotherapy. Eur J Echocardiogr
49. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr
50. Yildirim A, Tunaoglu FS, Pinarli FG, et al. Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity. Pediatr Cardiol
51. Karakurt C, Koçak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography
52. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function – a study in normals and dilated cardiomyopathy. J Cardiol
53. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation
54. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J
55. Casey DJ, Kim AY, Olszewski AJ. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. Am J Hematol
56. Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol
57. Savoia F, Gaddoni G, Casadio C, et al. A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy. Dermatol Online J
58. Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol
59. Calik AN, Celiker E, Velibey Y, et al. Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. Am J Emerg Med
60. Vincenzi B, Santini D, Frezza AM, et al. Docetaxel induced pericardial effusion. J Exp Clin Cancer Res
61. Agrawal V, Christenson ES, Showel MM. Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion. Case Rep Oncol
62. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol
63. Sardar MR, Kuntz C, Patel T. Primary pericardial mesothelioma unique case and literature review. Tex Heart Inst J
64. Maisch B, Seferovic PM, Ristic AD, et al. Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of CardiologyGuidelines on the diagnosis and management of pericardial diseases: executive summary. Eur Heart J
65. Posner MR, Cohen GI, Skarin AT. Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis. Am J Med
66. Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography. J Am Coll Cardiol
67. Brosius FC, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med
68. Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol)
69. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr
70. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist
71. Mantovani G, Madeddu C, Cadeddu C, et al. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist
72. Mele D, Rizzo P, Pollina AV, et al. Cancer therapy-induced cardiotoxicity: role of ultrasound deformation imaging as an aid to early diagnosis. Ultrasound Med Biol
73. Migrino RQ, Aggarwal D, Konorev E, et al. Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol
74. Cheung YF, Hong WJ, Chan GC, et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart
75. Bi X, Deng Y, Zeng F, et al. Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients. J Huazhong Univ Sci Technolog Med Sci
76. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart
77. Kang Y, Cheng L, Li L, et al. Early detection of anthracycline-induced cardiotoxicity using two dimensional speckle tracking echocardiography. Cardiol J
78. Stoodley PW, Richards DA, Hui R, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr
79. Poterucha JT, Kutty S, Lindquist RK, et al. Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr
80. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging
81. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol
82. Negishi K, Negishi T, Haluska BA, et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging
83. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: The value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol
84. Yu HK, Yu W, Cheuk DK, et al. New three-dimensional speckle-tracking echocardiography identifies global impairment of left ventricular mechanics with a high sensitivity in childhood cancer survivors. J Am Soc Echocardiogr
85. Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging
86. Badano LP, Boccalini F, Muraru D, et al. Current clinical applications of transthoracic three-dimensional echocardiography. J Cardiovasc Ultrasound
87. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol
88. Jenkins C, Moir S, Chan J, et al. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J
89. Muraru D, Badano LP, Piccoli G, et al. Validation of a novel automated border-detection algorithm for rapid and accurate quantitation of left ventricular volumes based on three-dimensional echocardiography. Eur J Echocardiogr
90. Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med
91. Neilan TG, Coelho-Filho OR, Pena-Herrera D, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol
92. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson
93. Pizzino F, Vizzari G, Qamar R, et al. Multimodality imaging in cardiooncology. J Oncol
94. Madonna R, Cadeddu C, Deidda M, et al. Cardioprotection by gene therapy: a review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol
95. Madonna R, Cadeddu C, Deidda M, et al. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev